Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05748600 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
A Phase 3 study of Asthma Attack and Eosinophilic Asthma, sponsored by Areteia Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT05748600: Active Phase 3 study of Asthma Attack and Eosinophilic Asthma, sponsored by Areteia Therapeutics.
NCT05748600 is a Phase 3 study of Asthma Attack and Eosinophilic Asthma that is active but no longer recruiting, run by Areteia Therapeutics. The registered enrollment target is 600 participants, below the 833-participant average among 4 other Asthma Attack trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05748600, a Phase 3 study of Asthma Attack and Eosinophilic Asthma, is active but no longer recruiting, sponsored by Areteia Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma to evaluate improvements in lung function, asthma control, and quality of life. In addition, the study will further evaluate the safety and tolerability of dexpramipexole in participants with eosinophilic asthma.
Primary Outcome
Pre-bronchodilator forced expiratory volume (pre-BD) FEV₁, absolute change from baseline, averaged over Weeks 20 and 24.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dexpramipexole Dihydrochloride
Study Locations (20)
California
- Research Site 40001-374 - Bakersfield
- Research Site 40001-227 - Encinitas
- Research Site 40001-349 - Huntington Beach
- Research Site 40001-485 - Inglewood
- Research Site 40001-440 - La Palma
- Research Site 40001-357 - Lancaster
- Research Site 40001-089 - Los Angeles
- Research Site 40001-362 - Mission Viejo
- Research Site 40001-449 - Napa
- Research Site 40001-062 - Newport Beach
- Research Site 40001-043 - Newport Beach
- Research Site 40001-380 - Redding
- Research Site 40001-434 - San Diego
- Research Site 40001-088 - San Jose
- Research Site 40001-359 - Upland
- Research Site 40001-003 - West Covina
- Research Site 40001-419 - Westminster
Arizona
- Research Site 40001-487 - Chandler
- Research Site 40001-462 - Peoria
- Research Site 40001-322 - Surprise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2023-01-30 |
| Est. Completion | 2025-12 |
| Phase | Phase 3 |
What the registry record for NCT05748600 still lists
NCT05748600 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 833-participant average among 4 other Asthma Attack trials with a reported enrollment target (28% lower).
The record links to 3 conditions, with Asthma Attack appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05748600 names 20 study sites across 2 states, led by California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05748600 about?
NCT05748600 is a clinical study titled "A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma". The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma to evaluate improvements in lung function, asthma control, and quality of life. In addition, the study will further evaluate the safety and tolerability ...
What is the current status of trial NCT05748600?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2023-01-30. Estimated completion is 2025-12.
What conditions does trial NCT05748600 study?
This clinical trial studies the following conditions: Asthma Attack, Eosinophilic Asthma, Asthma; Eosinophilic.
What interventions are being tested in trial NCT05748600?
The interventions under investigation include: Placebo (DRUG), Dexpramipexole Dihydrochloride (DRUG).
Who is sponsoring clinical trial NCT05748600?
This trial is sponsored by Areteia Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05748600 being conducted?
This trial has 20 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma Attack
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Wearable Electronic Breath Sound Sensing Device
RECRUITING
-
Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation
RECRUITING · Early Phase 1
-
Individualizing Treatment for Asthma in Primary Care (Full Study)
RECRUITING · Phase 4
-
User-Friendly Spirometer and Mobile App for Self-Management and Home Monitoring of Asthma Patients
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI